RE: GSK pays 2.1 billion plus a further potential billion1 Jun 2022 10:52
Further to that input from Thoth2, I had a quick look at Ventyx.
They are at a similar stage to us but they have 2 inhibitors already completed phase 1, and another in phase 1. More importantly, Q1 2022 financial results are slightly different to ours.
Cash Position: Cash, cash equivalents and marketable securities were $273.1 million as of March 31, 2022. We believe our current cash, cash equivalents and marketable securities are sufficient to fund planned operations into the first half of 2024.
I think that probably explains part of the difference in sp.
Question then begs to be asked: How on earth have they got such capital reserves?
Quick search bring ups this: ENCINITAS, Calif., March 9, 2021 /PRNewswire/ -- Ventyx Biosciences, Inc. ("Ventyx"), a clinical-stage biotechnology company advancing a pipeline of immune modulators to treat inflammatory diseases and autoimmune disorders, today announced the completion of a $114 million equity financing led by venBio Partners alongside new investors, including Third Point, RTW Investments, LP, Janus Henderson Investors, Wellington Management, OrbiMed, Surveyor Capital (a Citadel company), Farallon Capital, Vivo Capital, Logos Capital, Qiming Venture Partners USA, Cormorant Asset Management, and participation from founding investor New Science Ventures. In connection with the financing, Richard Gaster and Aaron Royston of venBio Partners and Jigar Choksey of Third Point will be joining the Ventyx Board of Directors.
Just over a year ago they received financing worth 114m dollars. However, they had to add 3 new people to the BOD. Is that something Tim and JR aren't keen on having? I would imagine they want to on-licence soon, whereas Ventyx may want to try and use their funds to do more trials. It is an interesting comparison but much more nuanced than just x4 sp...